[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"lupus-or-sle\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:lupus-or-sle":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,51,96],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":34,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100638972","periodontal-disease-in-rare-renal-disorders-perio-ra-re-100638972",false,"NCT07575347","Periodontal Disease in Rare Renal Disorders (PERIO-RA-RE)","Periodontal Inflammation in Rare Renal Disorders - A Cross-Sectional Controlled Observational Study Assessing the Burden and Phenotypes of Periodontal Disease","PERIO-RA-RE","Inclusion Criteria:\n\n* Age ≥18 years\n* Ability to provide written informed consent\n* At least 10 natural teeth present\n* Belonging to one of the predefined study groups:\n\n  1. Alport syndrome (genetically or clinically confirmed)\n  2. Fabry disease (enzymatically or genetically confirmed)\n  3. Tuberous sclerosis complex (according to established clinical or genetic criteria)\n  4. Systemic lupus erythematosus defined according to the 2019 EULAR\u002FACR or SLICC 2012 classification criteria, with renal involvement defined by at least one of the following: \\[1\\] Biopsy-proven lupus nephritis, \\[2\\] Persistent proteinuria (\\>0.5 g\u002Fday or equivalent), \\[3\\] Active urinary sediment (hematuria and\u002For cellular casts) consistent with lupus nephritis\n  5. Chronic kidney disease (CKD) of non-rare etiology: defined according to KDIGO criteria (eGFR \\\u003C60 ml\u002Fmin\u002F1.73 m² and\u002For markers of kidney damage)\n  6. Individuals without CKD, recruited from clinical or dental care settings as non-CKD controls\n\nExclusion Criteria:\n\n* Periodontal treatment within the last 6 months\n* Antibiotic therapy within the last 4 weeks\n* Pregnancy\n* Conditions precluding periodontal examination\n* Inability to comply with study procedures","ALL","18 Years",{"count":20,"type":21},100,"ESTIMATED","OBSERVATIONAL","This study aims to evaluate the burden and phenotypic spectrum of periodontal disease in patients with rare kidney disorders (such as Alport syndrome, Fabry disease, and tuberous sclerosis complex) and systemic lupus erythematosus (SLE), compared with chronic kidney disease (CKD) controls and population controls.\n\nThis is a cross-sectional, case-control observational study. Participants will undergo a single structured evaluation including a full-mouth periodontal examination, a clinical questionnaire, and collection of relevant clinical and nephrological data.\n\nThe primary objective is to compare the prevalence of periodontitis across study groups. Secondary objectives include characterization of periodontal disease severity, prevalence of gingivitis and xerostomia, and identification of disease-specific oral phenotypes.\n\nExploratory analyses will assess associations between periodontal disease and clinical variables such as kidney function, proteinuria, and immunosuppressive exposure.",[25,26,27,28,29,30,31,32,33],"Periodontal Disease","Periodontitis","CKD","Chronic Kidney Disease","Alport Syndrome","Fabry Disease","Lupus or SLE","Tuberous Sclerosis Complex (TSC)","Systemic Lupus Erythematosus (SLE)",[25,26,27,35,36,37,32,28],"Rare Kidney Diseases","Alport syndrome","Systemic Lupus Erythematosus","RECRUITING","2026-06-24",{"date":41,"type":42},"2026-06-26","ACTUAL",{"date":44,"type":42},"2026-05-04",{"date":46,"type":21},"2027-12-31",{"name":48,"class":49},"Stefan Lujinschi","OTHER",1,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":11,"sex":17,"minAge":58,"maxAge":59,"enrollmentInfo":60,"targetDuration":4,"studyType":62,"phases":63,"briefSummary":65,"conditions":66,"keywords":72,"overallStatus":86,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":50},"100592874","teams-engaged-in-accessible-mental-health-interventions-for-lupus-erythematosus-and-dermatomyositis-stress-100592874","NCT06999109","Teams Engaged in Accessible Mental Health Interventions for Lupus Erythematosus and Dermatomyositis Stress","TEAM-LEADS","Inclusion Criteria:\n\n* Diagnosis of juvenile-onset systemic lupus erythematosus (JSLE) or dermatomyositis (JDM)\n* Age 13-22 years old at time of enrollment\n\nExclusion Criteria:\n\n* Inability to complete surveys\u002Finterviews reliably\n* Lack of access to internet-enabled device;\n* Non-JSLE\u002FJDM diagnosis\n* History of myocardial infarction or cerebrovascular accident\n* Evidence of severe emotional distress defined as any of the following at time of screening: a) Patient Health Questionnaire for Adolescents (PHQ9A) score ≥ 15 indicating severe depression; b) PHQ9A suicidality item score \\> 0 indicating presence of any suicidal ideation; c) any other evidence noted of severe emotional distress per PI's judgment.","13 Years","22 Years",{"count":61,"type":21},25,"INTERVENTIONAL",[64],"NA","The objectives of this study are to determine if the 'Teams Engaged in Accessible Mental Health Interventions for Lupus Erythematosus and Dermatomyositis Stress' (TEAM-LEADS) intervention is feasible and acceptable to adolescents and young adults with lupus and dermatomyositis and whether it can help reduce stress and promote cardiovascular health behaviors in these individuals.",[67,68,69,70,71,31],"Lupus","Dermatomyositis, Juvenile","Dermatomyositis","Lupus Erythematosus","Lupus Erythematosus, Systemic",[73,74,75,67,69,76,77,78,79,80,81,82,83,84,85],"Stress","Depression","Anxiety","Pediatric Rheumatology","Physical Activity","Diet Quality","Sleep","Cardiovascular Health","Health Behaviors","Remote Intervention","Online Intervention","Co-Design","Intervention Refinement","NOT_YET_RECRUITING","2026-05-22",{"date":89,"type":42},"2026-05-27",{"date":91,"type":21},"2027-02-01",{"date":93,"type":21},"2029-01-15",{"name":95,"class":49},"Duke University",{"id":97,"slug":98,"hasResults":11,"nctId":99,"briefTitle":100,"officialTitle":101,"acronym":4,"eligibilityCriteria":102,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":103,"enrollmentInfo":104,"targetDuration":4,"studyType":62,"phases":105,"briefSummary":107,"conditions":108,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":50},"100598899","phase-4-effects-of-telitacicept-vs-cyclophosphamide-on-lupus-related-interstitial-lung-disease-100598899","NCT07077486","Effects of Telitacicept vs Cyclophosphamide on Lupus Related Interstitial Lung Disease","A Randomized, Positvel Controlled, Multicenter Study of Effects of Telitacicept vs Cyclophosphamide on Lupus Realted Interstitial Lung Disease","Inclusion Criteria:\n\n* Meet the 2019 EULAR\u002FACR classification criteria for systemic lupus erythematosus;\n* Male or non-pregnant female aged ≥ 18 years;\n* Diagnosis by high-resolution lung CT (HRCT) is clearly consistent with interstitial lung disease (ILD);\n* FEV1\u002FFVC%≥60% and diffusion function DLCO (measured value\u002Festimated value) ≥40%;\n* Patients voluntarily participate in this trial, have good compliance, and have the ability to understand and sign informed consent before the study.\n\nExclusion Criteria:\n\n* Alanine aminotransferase and\u002For aspartate aminotransferase (ALT\u002FAST) \\> 5 times the upper limit of normal;\n* severe chronic kidney disease (stage IV) or need for dialysis (estimated glomerular filtration rate (eGFR) \\\u003C 30ml\u002Fmin\u002F1.73m2);\n* Hemoglobin \\\u003C 80 g\u002FL;\n* WBC \\\u003C 2.0×10\\^9;\n* Platelet \\\u003C 50×10\\^9;\n* Is pregnant or breastfeeding;\n* Expected transfer to another hospital in a non-study site within 4 weeks (possibility of loss to follow-up);\n* Life expectancy does not exceed 24 weeks;\n* Have a history of severe allergies;\n* Patients with other serious lung diseases or other clinically significant serious abnormalities in the lungs;\n* Are using antitumor drugs, other immunosuppressants or immunomodulatory therapies;\n* Significant pulmonary hypertension;\n* Previous clinical or echocardiographic evidence of significant right heart failure;\n\n  1. Right heart catheterization showing cardiac index ≤ 2 L\u002Fmin\u002Fm2;\n  2. Pulmonary hypertension requiring treatment with epoprostenol\u002Ftraprostacyclin.\n* Patients with severe cardiovascular disease:\n\n  1. myocardial infarction within 6 months;\n  2. Unstable angina within 6 months.\n* Risk of bleeding, any of the criteria listed below:\n\n  1. known genetic predisposition to bleeding;\n  2. Patients who require the following treatments:\n\n  i. Fibrinolytic therapy, full-dose therapeutic anticoagulation (e.g., vitamin K antagonists, direct thrombin inhibitors, heparin, hirudin); ii. High-dose antiplatelet therapy. \\[Note: Prophylactic low-dose heparin or heparin flush solution (e.g., enoxaparin, 4000 I.U. S.C. per day) required for maintenance of indwelling intravenous access devices is not prohibited.) and prophylactic antiplatelet therapy (e.g., acetylsalicylic acid up to 325 mg\u002Fday, or clopidogrel at a dose of 75 mg\u002Fday, or other antiplatelet therapy at the same dose).\n* History of hemorrhagic central nervous system (CNS) events within 12 months;\n* Any of the following conditions within a period of 3 months:\n\n  1. hemoptysis or hematuria;\n  2. Active gastrointestinal bleeding or gastrointestinal ulcers;\n* Have previously undergone hematopoietic stem cell transplantation (HSCT), or plan to receive HSCT in the following year, or plan to undergo major surgery.\n* Women who are pregnant, breastfeeding or planning to become pregnant during the test;\n* 28 days before administration or 3 months after administration, women of childbearing age are unwilling or unable to use highly effective contraceptive methods;\n* According to the investigator's point of view, the patient has alcohol or drug abuse;\n* History of dysphagia or any gastrointestinal disease that affects drug\n* Patients with contraindications to the use of tatacept;\n* Subjects deemed unsuitable for participation in the study by the investigator.","80 Years",{"count":20,"type":21},[106],"PHASE4","Recent data indicate that Telitacicept is beneficial for lupus nephritis. Our goal is to determine whether Telitacicept is an effective and safe treatment, compared to standard-of-care Cyclophosphamide, for subclinical and clinical ILD in patients with early lupus.",[31,109,37],"Interstitial Lung Disease","2026-01-25",{"date":112,"type":42},"2026-01-27",{"date":114,"type":42},"2025-08-25",{"date":116,"type":21},"2027-03-25",{"name":118,"class":49},"Tongji Hospital"]